Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kezar Life Sciences (KZR) FCF Margin (2021 - 2025)

Kezar Life Sciences' FCF Margin history spans 5 years, with the latest figure at 4236.75% for Q2 2025.

  • For Q2 2025, FCF Margin fell 1038.0% year-over-year to 4236.75%; the TTM value through Sep 2025 reached 5458.48%, down 385188.0%, while the annual FY2023 figure was 1166.36%, N/A changed from the prior year.
  • FCF Margin for Q2 2025 was 4236.75% at Kezar Life Sciences, down from 4956.2% in the prior quarter.
  • Across five years, FCF Margin topped out at 7135.22% in Q4 2021 and bottomed at 290.59% in Q3 2023.
  • The 5-year median for FCF Margin is 5187.55% (2022), against an average of 4821.18%.
  • The largest YoY upside for FCF Margin was 104279bps in 2023 against a maximum downside of -578671bps in 2023.
  • A 5-year view of FCF Margin shows it stood at 7135.22% in 2021, then fell by -23bps to 5496.13% in 2022, then plummeted by -105bps to 290.59% in 2023, then skyrocketed by 1589bps to 4328.02% in 2024, then dropped by -2bps to 4236.75% in 2025.
  • Per Business Quant, the three most recent readings for KZR's FCF Margin are 4236.75% (Q2 2025), 4956.2% (Q1 2025), and 4328.02% (Q4 2024).